Once one of the hottest brands in biotech, Patrick Soon-Sh­iong’s next-gen can­cer brain­child Nan­tK­west has tak­en its lumps in re­cent years with lit­tle to show from its nat­ur­al killer cell plat­form. Now, with his cell ther­a­py play Im­mu­ni­ty­Bio mov­ing much faster in the clin­ic, Soon-Sh­iong will merge the two com­pa­nies to­geth­er to stream­line their mar­ket as­pi­ra­tions.

Nan­tK­west will re­verse merge with Soon-Sh­iong’s Im­mu­ni­ty­Bio in a stock-for-stock trans­ac­tion to bring 11 late-stage nat­ur­al killer and cell ther­a­py can­di­dates for on­col­o­gy and in­fec­tious dis­eases un­der a sin­gle roof, the com­pa­nies said Mon­day.

Rich Ad­cock

Soon-Sh­iong, a bil­lion­aire sur­geon and a big-tick­et name in bio­phar­ma, will stay on as ex­ec­u­tive chair­man while Rich Ad­cock, Nan­tK­west’s reign­ing CEO, will side­step in­to the same role at the new firm. The merg­er is set to close in the first half of 2021 with Im­mu­ni­ty­Bio in­vestors tak­ing the li­on’s share of the new com­pa­ny at a ful­ly di­lut­ed 78%.

Soon-Sh­iong stepped down from the CEO role in Oc­to­ber in fa­vor of Ad­cock five years in­to Nan­tK­west’s whirl­wind pub­lic of­fer­ing. The off-the-shelf nat­ur­al killer play, which Soon-Sh­iong de­scribed as his “can­cer moon shot,” was once the most valu­able IPO in biotech be­fore see­ing its share prices plum­met with lit­tle clin­i­cal da­ta to hold up and a very pub­lic re­con­sid­er­a­tion of the com­pa­ny’s hype.

For­tunes changed in ear­ly 2020 af­ter Soon-Sh­iong tout­ed ear­ly re­sults show­ing one pan­cre­at­ic can­cer pa­tient with a com­plete re­sponse, putting wind in the flag­ging com­pa­ny’s sales. On Fri­day, Nan­tK­west $NK shares closed trad­ing at $10.26.

So with lit­tle still to show for his ef­forts, Soon-Sh­iong will guide a new firm with a more di­ver­si­fied pipeline and a lit­tle bit more to show on the clin­i­cal side. Im­me­di­ate­ly fol­low­ing news of the merg­er Mon­day, Im­mu­ni­ty­Bio, a biotech tar­get­ing the in­nate and adap­tive im­mune sys­tem, trum­pet­ed re­sults from a Phase II/III tri­al show­ing its IL-15″su­per­ag­o­nist” Ank­ti­va (N-803) post­ed a 72% com­plete re­sponse rate in BCG un­re­spon­sive non-mus­cle in­va­sive blad­der can­cer af­ter 12 months of treat­ment.

That can­di­date comes from Im­mu­ni­ty­Bio’s im­munother­a­py fu­sion pro­tein, im­munomod­u­la­tor, and ade­n­ovirus plat­forms, which the biotech is al­so uti­liz­ing to chase a Covid-19 vac­cine. That can­di­date is an­gling for a Phase I hu­man study af­ter com­plete­ly clear­ing tri­al pri­mates’ air­ways in a U.S. gov­ern­ment-spon­sored tri­al, the com­pa­ny re­cent­ly said.

“What dis­tin­guish­es the merged en­ti­ty is the late stage im­munother­a­py prod­uct pipeline that is de­signed to elim­i­nate the need for high-dose chemother­a­py, im­prove the out­comes of cur­rent CAR T cell ther­a­pies, and ex­tend be­yond check­point in­hibitors,” Soon-Sh­iong said in a re­lease. “With 13 clin­i­cal tri­als across mul­ti­ple tu­mor types at Phase I to III and with the com­bined tal­ent in re­search, clin­i­cal de­vel­op­ment and man­u­fac­tur­ing, the merged en­ti­ty is poised to be a leader in the im­munother­a­py space.”

In all, the new­co will have 13 as­sets in clin­i­cal tri­als, ac­cord­ing to a re­lease, with IP run­ning out to 2035. The com­pa­ny will go on­line with a com­bined 200,000 square feet of man­u­fac­tur­ing and clin­i­cal space as it takes mul­ti­ple runs at the mar­ket.

New data from HHS show that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the US market, averaging about 33,000 courses administered per week in that time.

The FDA is offering more of an explanation of the guardrails around its program that may soon allow states to import prescription drugs in some select circumstances from Canada, but only if such imports will result in significant cost reductions for consumers.

While the agency has yet to sign off on any of the 5 state plans in the works so far, and PhRMA’s suit to block the Trump-era rule allowing such imports is stalled, the new Q&A guidance spells out the various restrictions that states will have to abide by, potentially signaling that a state approval is coming.

CureVac may have lost out on the initial mRNA race to bring a Covid-19 vaccine to the market, but it’s still eager to prove that it has what it takes to be a serious player in the field.

As it updates investors on its second-generation vaccine candidates for infectious diseases in Q1 results, the German biotech says it’s beefing up its oncology pipeline.

To that end, it has struck a new collaboration with Belgium’s myNEO, which boasts of a neoantigen discovery and selection platform, to identify new targets for mRNA immunotherapies.

Leading the way to increase access to cheaper drugs worldwide, Pfizer said Wednesday it will provide all current and future patent-protected medicines and vaccines available in the US or EU on a not-for-profit basis to about 1.2 billion people in 45 lower-income countries.

Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to sign on to this accord, which will also seek to blaze new paths for quick and efficient regulatory and procurement processes to reduce the usual delays in making new medicines and vaccines available in these countries.

Teva and Allergan have reached settlements with multiple states over their involvement in the opioid crisis. Their latest is worth 9 figures.

West Virginia attorney general Patrick Morrisey announced the newest settlement, worth $161.5 million, at a press conference on Wednesday. The deal would resolve claims that the companies helped fuel the state’s opioid epidemic. If it goes through, it could become the largest state-negotiated settlement in West Virginia’s history, according to Reuters.